Alan H. B. Wu

Q: What Schools Are Affiliated With Alan H. B. Wu

Alan H. B. Wu is affiliated with the following schools: Tufts University, Baylor College of Medicine, University of California, San Francisco

Alan H. B. Wu's AcademicInfluence.com Rankings

Alan H. B. Wu

Philosophy

#5622

World Rank

#8478

Historical Rank

Logic

#2862

World Rank

#3929

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Alan H. B. Wu's Degrees

Doctorate Medicine University of California, San Francisco
PhD Pharmacology University of California, San Francisco

Why Is Alan H. B. Wu Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan H. B. Wu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. (2002) (2742)
B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study (2002) (913)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. (2007) (720)
National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. (1999) (707)
Cardiac troponin and outcome in acute heart failure. (2008) (679)
B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. (2003) (525)
Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. (2003) (501)
Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. (2007) (487)
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. (2010) (485)
Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. (2005) (467)
European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. (2002) (400)
Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. (1998) (397)
Evaluation of imprecision for cardiac troponin assays at low-range concentrations. (2004) (394)
Automated assay of oxygen radical absorbance capacity with the COBAS FARA II. (1995) (391)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. (2007) (376)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. (2007) (376)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. (2010) (341)
High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure (2011) (339)
Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. (2003) (310)
Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. (2001) (284)
How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. (2006) (276)
Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. (2009) (269)
Test performance evaluation of SARS-CoV-2 serological assays (2020) (266)
N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. (2007) (266)
Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. (2003) (261)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. (2007) (255)
Cardiac troponin may be released by ischemia alone, without necrosis. (2010) (242)
Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. (2003) (235)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study (2013) (232)
Quality Specifications for Cardiac Troponin Assays (2001) (218)
National academy of clinical biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. (2003) (215)
Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. (1999) (207)
A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. (2002) (204)
Multiple Biomarkers for Risk Prediction in Chronic Heart Failure (2012) (195)
Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. (1998) (192)
Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction. (1994) (189)
Quality specifications for B-type natriuretic peptide assays. (2005) (187)
Myocardial infarction redefined: role of cardiac troponin testing. (2001) (184)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? (1999) (176)
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. (2008) (174)
The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. (2008) (173)
False increase of cardiac troponin I with heterophilic antibodies. (1998) (173)
Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? (2001) (172)
Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. (2005) (169)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. (2007) (168)
Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). (2013) (166)
Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. (2006) (163)
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study (2011) (156)
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. (2004) (149)
Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. (2010) (147)
Role of liquid chromatography–high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology (2012) (146)
Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. (2006) (143)
Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. (2004) (141)
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial (2012) (140)
Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. (2005) (140)
Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. (2001) (136)
Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. (2008) (133)
Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. (2003) (130)
Prognostic value of cardiac troponin T in unstable angina pectoris. (1995) (126)
Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. (2011) (126)
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance (2020) (125)
Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study (2004) (124)
A selected history and future of immunoassay development and applications in clinical chemistry. (2006) (124)
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. (2011) (123)
Tietz clinical guide to laboratory tests. (2006) (120)
Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. (1996) (117)
Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. (2001) (116)
Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies (2011) (115)
Multicenter evaluation of an automated assay for troponin I. (2002) (115)
Clinical and biomarker predictors of side effects from tamoxifen (2012) (113)
Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. (2013) (112)
National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. (2008) (108)
Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). (2013) (107)
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. (2010) (104)
Variability of biomarkers in patients with chronic heart failure and healthy controls (2016) (102)
Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. (1995) (101)
Adulteration of urine by "Urine Luck". (1999) (100)
Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. (2006) (98)
Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. (1998) (97)
Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. (1998) (94)
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated CopeptinClinical Perspective (2011) (92)
Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. (2009) (91)
Coronary angioplasty induces a systemic inflammatory response. (1997) (90)
The clinical effects of plasticizers, antioxidants, and other contaminants in medical polyvinylchloride tubing during respiratory and non-respiratory exposure. (2001) (88)
Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. (2013) (88)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. (2007) (85)
Interpreting laboratory results in transgender patients on hormone therapy. (2014) (85)
Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis. (2015) (84)
Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. (2005) (83)
Preparation of urine samples for liquid-chromatographic determination of catecholamines: bonded-phase phenylboronic acid, cation-exchange resin, and alumina adsorbents compared. (1985) (83)
The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. (2004) (81)
Test performance evaluation of SARS-CoV-2 serological assays (2020) (80)
Serum verapamil concentrations before and after Intralipid® therapy during treatment of an overdose (2011) (80)
Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage (2006) (77)
Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. (1994) (77)
Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. (2004) (76)
Short-term mortality risk in emergency department acute heart failure. (2011) (76)
Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute ischemic myocardial injury in a swine model. (1998) (75)
Dysfunctional Corin I555(P568) Allele Is Associated With Impaired Brain Natriuretic Peptide Processing and Adverse Outcomes in Blacks With Systolic Heart Failure: Results From the Genetic Risk Assessment in Heart Failure Substudy (2009) (74)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. (2008) (70)
Multiple MDMA (Ecstasy) Overdoses at a Rave Event (2013) (69)
Physiogenomic association of statin‐related myalgia to serotonin receptors (2007) (67)
Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction. (2000) (66)
Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB and BB from macro forms of creatine kinase isoenzymes in patients and healthy individuals. (1982) (66)
Troponin release--reversible or irreversible injury? Should we care? (2012) (65)
Use of genetic and nongenetic factors in warfarin dosing algorithms. (2007) (65)
Creatine kinase MB isoforms in patients with skeletal muscle injury: ramifications for early detection of acute myocardial infarction. (1992) (63)
Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. (1994) (61)
Creatine kinase isoforms in ischemic heart disease. (1989) (61)
Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. (2000) (60)
Mechanisms of statin-induced myalgia assessed by physiogenomic associations. (2011) (59)
Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. (2016) (58)
Sex-Specific 99th Percentile Upper Reference Limits for High Sensitivity Cardiac Troponin Assays Derived Using a Universal Sample Bank. (2020) (58)
Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites. (2006) (57)
International survey on the use of cardiac markers. (2001) (56)
Early diagnosis of acute myocardial infarction by rapid analysis of creatine kinase isoenzyme-3 (CK-MM) sub-types. (1987) (56)
Comparison of acute rest myocardial perfusion imaging and serum markers of myocardial injury in patients with chest pain syndromes (1999) (54)
Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. (2002) (54)
CEDIA for screening drugs of abuse in urine and the effect of adulterants. (1995) (54)
Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. (2013) (54)
Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening. (2010) (53)
Role of rapid immunoassays for urgent ("stat") determinations of creatine kinase isoenyme MB. (1989) (53)
Analysis of the Albumin cobalt Binding (ACBTM) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction (2007) (53)
Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. (2012) (53)
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. (2021) (53)
Macro creatine kinase types 1 and 2: clinical significance in neonates and children as compared with adults. (1983) (52)
Simultaneous Assessment of Unprocessed ProBNP1-108 in Addition to Processed BNP32 Improves Identification of High-Risk Ambulatory Patients With Heart Failure (2010) (52)
Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. (2010) (51)
Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance (2011) (51)
Relationship of B‐type natriuretic peptide and anemia in patients with and without heart failure: A substudy from the Breathing Not Properly (BNP) Multinational Study (2005) (51)
The analysis of thebaine in urine for the detection of poppy seed consumption. (1997) (50)
Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays (2013) (49)
Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material. (1999) (49)
False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. (2002) (49)
Plasticizers, antioxidants, and other contaminants found in air delivered by PVC tubing used in respiratory therapy. (2003) (48)
Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. (2005) (48)
Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain: case report series. (2009) (48)
Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay (2017) (47)
Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study (2012) (47)
Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. (1999) (47)
The ischemia-modified albumin biomarker for myocardial ischemia. (2003) (47)
Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty (1996) (45)
Proposals from the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): strategies and concepts on standardization of cardiac marker assays. (1999) (44)
B‐type Natriuretic Peptides for the Prediction of Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study (2014) (44)
In-vitro production of ethanol in urine by fermentation. (1995) (43)
Comparative analysis of cardiac troponin i and creatine kinase‐MB as markers of acute myocardial infarction (1997) (43)
Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. (2011) (42)
Candidate reference method for determining creatinine in serum: method development and interlaboratory validation. (1990) (42)
Prognostic value of cardiac troponin I in patients with chest pain. (1996) (42)
Bilirubin interference with determination of uric acid, cholesterol, and triglycerides in commercial peroxidase-coupled assays, and the effect of ferrocyanide. (1986) (42)
Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients. (2016) (42)
A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). (2000) (41)
Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. (2004) (41)
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. (2021) (41)
Markers for Early Detection of Cardiac Diseases (2005) (40)
Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). (1999) (39)
Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay. (2014) (39)
Total Analytic Error for Low Cardiac Troponin Concentrations (≤10 ng/L) by Use of a High-Sensitivity Cardiac Troponin Assay. (2017) (38)
Biological and Analytical Variation of Clinical Biomarker Testing: Implications for Biomarker-guided Therapy (2013) (38)
Hyperviscosity caused by hyaluronic acid in serum in a case of Wilms' tumor. (1984) (38)
Release of cardiac troponin from healthy and damaged myocardium (2017) (37)
Specificity of a high-sensitivity cardiac troponin I assay using single-molecule-counting technology. (2009) (37)
Cannabis Intoxication Case Series: The Dangers of Edibles Containing Tetrahydrocannabinol (2017) (36)
Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal alcohol metabolism. (2007) (36)
Clinical Chemistry: Theory, Analysis, Correlation, 3rd ed. Lawrence A. Kaplan and Amadeo J. Pesce. St. Louis, MO: Mosby, 1996, 1064 pp, $69.95. ISBN 0-8151-5243-4 (1997) (35)
Elevated BNP is Associated with Vasospasm-Independent Cerebral Infarction Following Aneurysmal Subarachnoid Hemorrhage (2011) (35)
Cardiac troponins T and I before and after renal transplantation. (1997) (35)
Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study. (2009) (34)
Quality Control Practices for Chemistry and Immunochemistry in a Cohort of 21 Large Academic Medical Centers (2018) (34)
Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain. (1997) (34)
Influence of imprecision on ROC curve analysis for cardiac markers. (2006) (33)
The use of lamellar body counts to predict fetal lung maturity in pregnancies complicated by diabetes mellitus. (2002) (33)
Short- and long-term cardiac troponin I analyte stability in plasma and serum from healthy volunteers by use of an ultrasensitive, single-molecule counting assay. (2009) (33)
What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml? (2003) (32)
ST2 in emergency department chest pain patients with potential acute coronary syndromes. (2007) (32)
Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: results from the Breathing Not Properly Multinational Study. (2006) (31)
Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants. (2003) (31)
Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. (2010) (31)
Cardiac Markers (2003) (31)
Improving the utilization of clinical laboratory tests. (1998) (30)
Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis. (1999) (30)
Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. (2009) (30)
Clinical applications of muscle enzymes and proteins (1992) (30)
Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. (2013) (29)
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice (2013) (29)
Comparison of enzyme immunoassay and immunoprecipitation for creatine kinase MB in diagnosis of acute myocardial infarction. (1985) (29)
The Hawaii clopidogrel lawsuit: the possible effect on clinical laboratory testing. (2015) (29)
Antiquated tests within the clinical pathology laboratory. (2010) (28)
Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. (2020) (28)
Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization (2018) (28)
Synthetic agents off the darknet: a case of U-47700 and phenazepam abuse (2017) (27)
Applications of forensic identity testing in the clinical laboratory. (1999) (27)
Long-term biological variation in cardiac troponin I. (2012) (27)
Analytical and clinical evaluation of new diagnostic tests for myocardial damage. (1998) (27)
Diagnostic performance of cardiac Troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. (2015) (27)
Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study. (2011) (26)
The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. (2004) (26)
Marathoner's heart? (2006) (26)
Proenkephalin (PENK) as a Novel Biomarker for Kidney Function. (2017) (26)
A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. (1999) (25)
Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. (2015) (25)
Use of cardiac markers as assessed by outcomes analysis. (1997) (24)
Prognostic value of the Ortho Vitros cardiac troponin I assay in patients with symptoms of myocardial ischemia. Risk stratification using European Society of Cardiology/American College of Cardiology recommended cutoff values. (2003) (24)
Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. (1998) (23)
Diagnostic and Prognostic Role of Myoglobin in Patients With Suspected Acute Coronary Syndrome (2000) (23)
Definitive identification of an exceptionally high methanol concentration in an intoxication of a surviving infant: methanol metabolism by first-order elimination kinetics. (1995) (23)
Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. (1999) (23)
Characterization of drug interferences caused by coelution of substances in gas chromatography/mass spectrometry confirmation of targeted drugs in full-scan and selected-ion monitoring modes. (1994) (23)
False-positive urine phencyclidine immunoassay screen result caused by interference by tramadol and its metabolites. (2012) (23)
Minimal standards for the performance and interpretation of toxicology tests in legal proceedings. (1999) (22)
5-oxoprolinemia causing elevated anion gap metabolic acidosis in the setting of acetaminophen use. (2012) (22)
Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. (2011) (22)
Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. (2007) (22)
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. (2010) (21)
Counterfeit Norco Poisoning Outbreak - San Francisco Bay Area, California, March 25-April 5, 2016. (2016) (21)
The conversion of ephedrine to methamphetamine and methamphetamine-like compounds during and prior to gas chromatographic/mass spectrometric analysis of CB and HFB derivatives (1992) (21)
Gene expression profiles help identify the Tissue of Origin for metastatic brain cancers (2010) (21)
Accuracy of the initial diagnosis among patients with an acutely altered mental status (2012) (21)
Mass spectrometry in the clinical laboratory: how have we done, and where do we need to be? (2009) (20)
Diagnostic Value of Nucleocapsid Protein in Blood for SARS-CoV-2 Infection (2021) (20)
Diminished need for folate measurements among indigent populations in the post folic acid supplementation era. (2007) (20)
Validation of NACB and IFCC guidelines for the use of cardiac markers for early diagnosis and risk assessment in patients with acute coronary syndromes. (2001) (20)
Diagnostic and prognostic role of myoglobin in patients with suspected acute coronary syndrome. North-Württemberg Infarction Study (NOWIS) Group. (2000) (20)
Cardiac troponin: friend of the cardiac physician, foe to the cardiac patient? (2006) (20)
Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction (2020) (20)
Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction. (2003) (20)
The Era for High-Sensitivity Cardiac Troponin Has Begun in the US (Finally). (2017) (20)
Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse. (1995) (19)
Characterization of 107 Genomic DNA Reference Materials for CYP 2 D 6 , CYP 2 C 19 , CYP 2 C 9 , VKORC 1 , and UGT 1 A 1 A GeT-RM and Association for Molecular Pathology Collaborative Project (2010) (19)
The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. (2000) (19)
Evaluation of Tamoxifen and Metabolites by LC-MS/MS and HPLC Methods (2014) (19)
Short-term (90 min) diagnostic performance for acute non-ST segment elevation myocardial infarction and 30-day prognostic evaluation of a novel third-generation high sensitivity troponin I assay. (2012) (18)
An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome (2017) (18)
High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. (2006) (18)
Detection and interpretation of lysergic acid diethylamide results by immunoassay screening of urine in various testing groups. (1997) (18)
Development and Validation of a Novel LC-MS/MS Opioid Confirmation Assay: Evaluation of β-glucuronidase Enzymes and Sample Cleanup Methods. (2016) (18)
Evaluation of two-dimensional cytometric lamellar body counts on the ADVIA 120 hematology system for estimation of fetal lung maturation. (2004) (18)
N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study. (2007) (18)
KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. (2011) (17)
Multi-site clinical evaluation of the Xpert(®) HIV-1 viral load assay. (2016) (17)
Measurement of creatine kinase MM sub-type by anion-exchange liquid chromatography. (1985) (17)
Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? (2009) (17)
Creation of a Universal Sample Bank for Determining the 99th Percentile for Cardiac Troponin Assays. (2017) (17)
The effect of pathologic substances and adulterants on the DNA typing of urine. (1998) (17)
Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials. (2004) (17)
Biological variation of β-sitosterol, campesterol, and lathosterol as cholesterol absorption and synthesis biomarkers. (2014) (17)
Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. (1999) (17)
Gene expression profiling from formalin-fixed, paraffin-embedded tissue for tumor diagnosis. (2011) (16)
Reassessment of creatine kinase BB as a marker for cancer of the prostate, breast, and lung. (1987) (16)
Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score (2012) (16)
Improving the 510(k) FDA process for cardiac troponin assays: in search of common ground. (2014) (16)
An unusual case of toluene-induced metabolic acidosis. (1988) (16)
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors (2017) (16)
Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites. (2011) (16)
High-Resolution Mass Spectrometry for Untargeted Drug Screening. (2016) (16)
A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. (2008) (15)
Early detection of acute coronary syndromes and risk stratification by multimarker analysis. (2007) (15)
How specific is cardiac troponin? (2000) (15)
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment (2011) (15)
Cardiotoxicity in a citalopram and olanzapine overdose. (2013) (14)
Comprehensive Age and Sex 99th Percentiles for a High-Sensitivity Cardiac Troponin I Assay. (2018) (14)
99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. (2020) (14)
Vitamin D status of county hospital patients assessed by the DiaSorin LIAISON® 25-hydroxyvitamin D assay. (2011) (14)
B-type natriuretic peptide and its clinical utility in patients with heart failure. (2001) (13)
Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial (2012) (13)
Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation. (2009) (13)
Beside B-type natriuretic peptide in the emergency diagnosis of systolic and nonsystolic heart failure: Results from the breathing not properly (BNP) multinational study (2003) (13)
ST2 in Emergency Department Chest Pain Patients with Potential Acute Coronary Syndromes (2007) (13)
Identification of urine specimen donors by the PM+DQA1 amplification and typing kit. (1996) (13)
Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin (2003) (13)
A Liquid-Chromatography High-Resolution Mass Spectrometry Method for Non-FDA Approved Benzodiazepines. (2018) (13)
Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. (2005) (13)
High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. (2008) (13)
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study (2017) (13)
Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records (2021) (12)
Reference values for cardiac troponins I and T in a goal-oriented concept of health: cardiac marker values in a series of outpatients without acute coronary syndromes. (2004) (12)
Performance characteristics of a high-sensitivity cardiac troponin assay using plasma and whole blood samples. (2017) (12)
National academy of clinical biochemistry laboratory medicine practice guidelines: Point of care testing, oversight, and administration of cardiac biomarkers for acute coronary syndromes (2007) (12)
Recombinant creatine kinase proteins and proposed standards for creatine kinase isoenzyme and subform assays. (1993) (12)
Biomarkers for cholesterol absorption and synthesis in hyperlipidemic patients: role for therapeutic selection. (2014) (12)
Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial (2015) (12)
Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. (2020) (12)
Pharmacogenomic testing and response to warfarin (2015) (12)
Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly. The SENECA study. (2000) (11)
Analytical assay characterization for 1-108 pro-B-type natriuretic peptide on the BioPlex 2200 analyzer. (2009) (11)
Reducing the inappropriate utilization of clinical laboratory tests. (1997) (11)
Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women. (2020) (11)
Introduction to Coronary Artery Disease (CAD) and Biochemical Markers (1998) (11)
C3435T polymorphism of MDR1 gene with warfarin resistance. (2013) (11)
An enzyme-linked immunosorbent assay for urinary screening of fentanyl citrate abuse. (1995) (11)
Serum cardiac troponin T concentrations in hospitalized patients without acute myocardial infarction. (1996) (11)
Analytical validation of novel cardiac biomarkers used in clinical trials. (2015) (11)
Clinical evaluation of an automated chemical inhibition assay for lactate dehydrogenase isoenzyme 1. (1990) (11)
Ionized calcium monitoring during liver transplantation. (1987) (10)
Response to Letter to the Editor Regarding Article, “Simultaneous Assessment of Unprocessed ProBNP1–108 in Addition to Processed BNP32 Improves Risk Stratification in Ambulatory Patients with Systolic Heart Failure” (2010) (10)
Confirmed glyburide poisoning from ingestion of "street Valium". (2012) (10)
Quality specifications in thyroid diseases. (2004) (10)
The Role of Cardiac Troponin in the Recent Redefinition of Acute Myocardial Infarction (2004) (10)
Tumor markers. Physiology, pathobiology, technology, and clinical applications (2003) (10)
Analytical Issues for Clinical Use of Cardiac Troponin (2006) (10)
Point-of-Care Testing for Conventional Cardiac Markers (2006) (10)
Creatine Kinase, Isoenzymes, and Variants (1998) (10)
A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients (2021) (9)
Evaluation of Intraosseous Fluid as an Alternative Biological Specimen in Postmortem Toxicology. (2018) (9)
BNP test utilization for CHF in community hospital practice. (2003) (9)
High-sensitivity cardiac troponin assays: what analytical and clinical issues need to be addressed before introduction into clinical practice? Interview by Fred S. Apple. (2010) (9)
Myocardial Infarction Can Be Safely Excluded by High‐sensitivity Troponin I Testing 3 Hours After Emergency Department Presentation (2020) (9)
Simultaneous presence of IgA- and IgG-CK-BB in a patient without myocardial infarction. (1987) (9)
What causes elevated B-type natriuretic peptide in patients without heart failure? (2003) (9)
Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. (2015) (9)
Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease. (2017) (9)
Clinical trials for pharmacogenomics testing for warfarin dosing: Relevance to general community practices (2011) (9)
Short-and Long-Term Biological Variation in Cardiac Troponin I with a High-Sensitivity Assay : Implications for Clinical Practice (2008) (8)
Etiologies of troponin elevation in critically ill patients with gastrointestinal bleeding. (2009) (8)
Diagnostic performance of a new automated heterophile antibody test in adults and children. (2008) (8)
Creatine Kinase MM and MB Isoforms (1992) (8)
Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspnea. (2009) (8)
Analytical performance of cardiac troponin assays - current status and future needs. (2020) (8)
Therapeutic drug monitoring of tamoxifen using LC-MS/MS. (2012) (8)
Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification (2020) (8)
Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument (2020) (8)
Pharmacogenomic-guided dosing for warfarin: too little too late? (2018) (8)
Release of cardiac troponin using a high sensitivity assay after exercise: Type 2 acute myocardial infarction? (2015) (8)
Impact of revised NIDA guidelines for methamphetamine testing in urine. (1992) (8)
Prescription compliance or illicit designer drug abuse? (2012) (8)
Biological variation of the osmolality and the osmolal gap. (2014) (8)
Cardiac troponin I is present in plasma of type 1 myocardial infarction patients and patients with troponin I elevations due to other etiologies as complex with little free I. (2019) (8)
Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay (2018) (7)
Role of qualitative choriogonadotropin assays in diagnosis of ectopic pregnancy. (1987) (7)
Analytical and clinical concordance of free light chain assay (2018) (7)
Multicenter assessment of a hemoglobin A1c point-of-care device for diagnosis of diabetes mellitus. (2018) (7)
Results of novel cardiac biomarkers in Tako-tsubo cardiomyopathy. (2012) (7)
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up (2020) (7)
Quantitative determination of theophylline by an automated chemiluminescent immunoassay in serum and plasma: comparison to other methods of analysis. (1997) (7)
A comparison of methods for evaluation of a case of suspected macro-aspartate aminotransferase. (2016) (7)
Gender-specific decision limits for cardiac troponin for risk stratification? (2009) (7)
Falsely high serum creatinine concentration associated with severe methanol intoxication. (1983) (7)
Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay (2019) (7)
When the Drug of Choice Is a Drug of Confusion (2005) (7)
Clinical utility of an LC-MS/MS seizure panel for common drugs involved in drug-induced seizures. (2009) (7)
Reflex testing I: algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment. (1999) (7)
Copeptin to rule out myocardial infarction in Blacks versus Caucasians (2019) (6)
Chapter 9.12 – Cardiac Markers (2013) (6)
B-type natriuretic peptide levels are inversely related to body mass index in patients with heart failure (2003) (6)
The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk. (2014) (6)
Extracellular vesicles released in blood of COVID-19 patients: mechanism for detection of cardiac troponin after myocardial injury? (2020) (6)
Pharmacogenomic testing for warfarin dosing: we are ready now (2009) (6)
"On Vivo" and Wearable Clinical Laboratory Testing Devices for Emergency and Critical Care Laboratory Testing. (2019) (6)
Multi-wavelength spectrophotometric analysis for detection of xanthochromia in cerebrospinal fluid and accuracy for the diagnosis of subarachnoid hemorrhage. (2013) (6)
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? (2010) (6)
Reflex testing II: evaluation of an algorithm for use of cardiac markers in the assessment of emergency department patients with chest pain. (1999) (6)
Reduction in extraction efficiency of charged particles from the ion source as the cause of matrix effects in the GC-MS analysis of drugs. (1997) (6)
Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics. (2013) (6)
Role of Serum Biochemical Markers in Clinical Trials (1998) (6)
A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum (2021) (6)
cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events (2020) (6)
Impact of the history of congestive heart failure on accuracy of BNP in the emergency diagnosis of heart failure: results from the breathing not properly (BNP) multinational study (2004) (6)
Biological variation of immunoglobulin heavy chain-light chain pairs in serum. (2014) (6)
Development and preliminary validation of infrared spectroscopic device for transdermal assessment of elevated cardiac troponin (2022) (5)
B-type natriuretic peptide levels in patients in the emergency department with possible heart failure and previous stable angina pectoris and/or healed myocardial infarction. (2005) (5)
Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory (2011) (5)
The use of plasma metanephrine to normetanephrine ratio to determine epinephrine poisoning. (2005) (5)
Natriuretic peptides. The Hormones of the Heart (2007) (5)
CD4 Lymphocyte Enumeration and Hemoglobin Assessment Aid for Priority Decisions: A Multisite Evaluation of the BD FACSPresto™ System (2017) (5)
Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize? (2006) (5)
Establishment of a High-Resolution Liquid Chromatography-Mass Spectrometry Spectral Library for Screening Toxic Natural Products. (2021) (5)
Bright Green Serum (2007) (5)
State-wide hospital clinical laboratory plan for measuring cholinesterase activity for individuals suspected of exposure to nerve agent chemical weapons (2008) (5)
Abstract 15518: Novel SNPs Associated with Warfarin Dose in a Large Multicenter Cohort of African Americans: Genome Wide Association Study and Replication Results (2011) (5)
Multicenter evaluation of the Bayer Immuno I CA 15-3 assay. (1998) (5)
Necessity of hospitalization and stress testing in low risk chest pain patients (2017) (5)
A Thin-Film Interferometry-Based Label-Free Immunoassay for the Detection of Daratumumab Interference in Serum Protein Electrophoresis. (2019) (4)
Stability of cholesterol gall stones after 165 years of burial. (2003) (4)
Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins. (2016) (4)
Quantitation of Infliximab and Detection of Antidrug Antibodies in Serum by Use of Surface Plasmon Resonance. (2018) (4)
Chronic alcohol use does not protect against COVID-19 infection (2020) (4)
Integrity of Urine Specimens for Toxicological Analysis - Adulteration, Mechanisms of Action, and Laboratory Detection. (1998) (4)
Images in clinical medicine. Bright green serum. (2007) (4)
Evaluation of the Cepheid Xpert® HCV Viral Load Assay (2015) (4)
A Multicenter Evaluation of a Nongel Mechanical Separator Plasma Blood Collection Tube for Testing of Selected Therapeutic Drugs. (2020) (4)
737–4 Serum Cardiac Troponln T Measurements in Unstable Angina: An Early, Accurate Marker of Increased Risk (1995) (4)
The standards for reporting diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate? (2016) (4)
Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease. (2017) (4)
The role of cardiac imaging and biochemical markers in patients with acute chest pain. (1996) (4)
Anticholinergic toxicity associated with ingestion of water containing lupini bean extract (2017) (4)
Ectopic production of creatine kinase MB: updated evaluation by mass assays. (1997) (4)
Standards of Laboratory Practice : Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases (1999) (4)
Improved quantitative Apt test for detecting fetal hemoglobin in bloody stools of newborns. (1993) (4)
Development and validation of an LC-MS/MS sulfonylurea assay for hypoglycemia cases in the emergency department. (2016) (4)
Analysis of codeine positivity in urine of pain management patients. (2015) (4)
The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea (2012) (4)
Folate testing: time to retire your VCR. (2014) (3)
Stratus CS Stat Fluorometric Analyzer (2002) (3)
A 23‐Gene Classifier urine test for prostate cancer prognosis (2021) (3)
Return-to-Play Guidelines for Athletes After COVID-19 Infection. (2020) (3)
Narrowed reference intervals for complete blood count in a multiethnic population (2019) (3)
The independent contribution to elevations in B-type natriuretic peptide from atrial fibrillation (2002) (3)
Choosing the Right Benzodiazepine Assay: Impact on Clinical Decision Making (2010) (3)
COMPARISON OF CONVENTIONAL AND HIGH-SENSITIVITY TROPONIN IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN: A COLLABORATIVE META-ANALYSIS (2014) (3)
Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection? (2020) (3)
Mechanism of differential inhibition of lactate dehydrogenase isoenzymes in the BMC LD-1 assay. (1992) (3)
Uncovering heart failure in patients with bronchospasm: Rationale for the early use of B-type natriuretic peptide in the emergency department (2003) (3)
Standardization of assays for clinically important enzymes that have high biologic variation: what is all the fuss about? (2010) (3)
New Biochemical Markers for Heart Diseases (1998) (3)
Homocysteine screening of a female Hispanic population. (1999) (3)
The birth and potential death of IL28B genotyping for hepatitis C therapy. (2015) (3)
An inexpensive lyophilized quality-control material for cardiac isoenzymes. (1984) (3)
Guidelines and recommendations in laboratory medicine. (2002) (3)
MA23.03 Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma-Protein Based Biomarker Assay (2018) (3)
Automated quantification of choriogonadotropin: analytical correlation between serum and urine with creatinine correction. (1987) (3)
Predicting mortality after elective open-heart surgery using midregional-proadrenomedullin: is it time to scalp Acute Physiology and Chronic Health Evaluation IV? (2015) (3)
' s personal copy Association between anaemia and N-terminal proB-type natriuretic peptide ( NT-proBNP ) : Findings from the Heart and Soul Study (2007) (3)
B-type natriuretic peptide adds to clinical judgement in the diagnosis of heart failure: a bayesian analysis from the BNP multinational study (2002) (3)
Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2 (2012) (3)
Multicenter analytical evaluation of an automated immunoassay for total plasma homocysteine. (2000) (3)
Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. (2013) (2)
A Label-Free SARS-CoV-2 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients (2021) (2)
A case of a rapid drop in lactate. (2011) (2)
120 Plasma Inducible Nitric Oxide Synthase as a Biomarker for Sepsis in Emergency Department Patients (2016) (2)
The effect of diabetes on B-type natriuretic peptide levels in patients with acute dyspnea (2002) (2)
Analytical validation of a novel multi-analyte plasma test for lung nodule characterization (2018) (2)
Cocaine use is associated with a higher prevalence of elevated ST2 concentrations. (2017) (2)
Further insight on amylase and lipase. (2006) (2)
Erratum: Troponin release - Reversible or irreversible injury? Should we care? (Clinical Chemistry (2012) 58 (148-150) DOI: 10.1373/clinchem.2011.173070) (2012) (2)
Abstract 12104: Absolute and Relative Changes (Delta) in Troponin I for Early Diagnosis of Myocardial Infarction: Results of a Prospective Multicenter Trial (2014) (2)
Pharmacogenomic Testing in Current Clinical Practice (2011) (2)
High-sensitivity cardiac troponin testing for primary care: analytical assay considerations required before widespread implementation. (2016) (2)
Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers (2003) (2)
Biomarkers in Acute Cardiac Syndromes (1999) (2)
Reflex testing III: efficient use of laboratory markers for anemia. (2004) (2)
PEER REVIEWED PUBLICATIONS 1. Ali YS, Maron DJ. Screening for coronary disease in diabetes: when and how. Clin Diabetes 2006; 24:169- 173. (2007) (2)
Screening for drugs of abuse by Syva Emit® II reagents on the BM/Hitachi 717 analyzer (1992) (2)
Primary results of the BNP multinational study: B-type natriuretic peptide in the emergency diagnosis of heart failure (2002) (2)
Biological variation: from principles to practice: Callum G. Fraser, AACC Press, Washington, DC, 2001, ISBN 1-890883-49-2; $30.00, 151 pp., AACC members 22.00 (2003) (2)
N-Terminal ProB-Type Natriuretic Peptide and Inducible Ischemia in the Heart and Soul Study (2009) (2)
A new ultra-high sensitivity troponin I assay for chest pain patients with no evidence of troponin I using a conventional assay. (2015) (2)
Report of the Third Conference on Education in Clinical Chemistry. (1976) (1)
N-Terminal Pro-B-Type Natriuretic Peptide as a Diagnostic Test for Ventricular Dysfunction in Patients With Coronary Disease (2016) (1)
The biological variation of plasma proenkephalin: data from a stable heart failure cohort (2018) (1)
Drs. Wu and Apple respond (2002) (1)
ASSOCIATION OF COCAINE AND AMPHETAMINE USE WITH TROPONIN I CONCENTRATIONS (2017) (1)
Economics of Pharmacogenomic Testing in Clinical Practice (2011) (1)
Echocardiographic wall motion abnormality or serum troponin I for predicting prognosis in patients with unstable angina (1998) (1)
859-2 Utility of B-natriuretic peptide levels in predicting outcome of hospitalized patients with congestive heart failure: Results of the breathing not properly (BNP) multinational study (2004) (1)
COPEPTIN PROVIDES PROGNOSTIC VALUE IN PATIENTS WITH ACUTE CHEST PAIN (2014) (1)
ASSOCIATION OF COCAINE AND AMPHETAMINE USE WITH TROPONIN I CONCENTRATIONS (2017) (1)
An Epidemiological Study To Evaluate the Incidence of Activated Protein C Resistance in the General Population Using a Polymerase Chain Reaction-Mediated Restriction Fragment Length Polymorphism Assay:Implications for the Critical Care Patient (1997) (1)
B-Type Natriuretic Peptide Biochemistry and Measurement (2013) (1)
A washer-dryer system for cuvette rotors used in the Cobas-Bio Centrifugal Analyzer. (1982) (1)
Diagnostic enzymology. (1989) (1)
XW-100: First FDA CLIA-Waived CBC Analyzer Designed for Physician Office Use. (2019) (1)
Mild Positive Human Chorionic Gonadotropin in a Perimenopausal Female: Normal, Malignancy, or Phantom? (2009) (1)
Upper Reference limits and percent measurable concentrations using a universal sample bank for high sensitivity cardiac troponin I using a point-of-care assay. (2020) (1)
A rapid BNP assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter study (2002) (1)
Prognosis is worse with elevated cardiac troponin in nonacute coronary syndrome compared with acute coronary syndrome (2022) (1)
Practice Guidelines : Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure (2007) (1)
Short-and Long-Term Cardiac Troponin I Analyte Stability in Plasma and Serum from Healthy (1)
Issues in Translation of Pharmacogenomics into Clinical Practice (2011) (1)
Cardiac markers: cost-effective triage for MI admission and therapy. (2002) (1)
Improving the 510k FDA Process for Cardiac Troponin Assays: In Search of Common Ground (2014) (1)
PROGNOSTIC SIGNIFICANCE OF AN ELEVATED CONVENTIONAL OR HIGH-SENSITIVITY CARDIAC TROPONIN IN PATIENTS WITH CHEST PAIN WITH AND WITHOUT A DIAGNOSIS OF MYOCARDIAL INFARCTION (2015) (1)
N-TERMINAL FRAGMENT OF THE PROHORMONE BRAIN-TYPE NATRIURETIC PEPTIDE (NT-PROBNP) VS. BNP FOR PREDICTING ADVERSE OUTCOMES IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART AND SOUL STUDY (2012) (1)
Pathophysiology of Acute Coronary Syndromes (1998) (1)
Is there a continual role for serum creatine kinase and myoglobin testing in the era of high sensitivity troponin assays (2018) (1)
Therapeutic Drug Monitoring to Support Clinical Pharmacogenomics (2012) (1)
Promoting the value of precision medicine to the public: the power of story telling (2016) (1)
50 years of CCA (2006) (1)
Cardiac Troponin Composition Characterization after Non ST-Elevation Myocardial Infarction: Relation with Culprit Artery, Ischemic Time Window, and Severity of Injury. (2020) (1)
B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the BNP multinational study (2003) (1)
Chinese Congress of Clinical Chemistry and Laboratory Medicine 2000 (2001) (1)
Plasma cBIN1 Score (CS) Identifies HFpEF and Can Predict Cardiac Hospitalization in Stable Ambulatory Patients (2018) (0)
Review of: Alcohol and Its Biomarkers (2017) (0)
Bilirubin Interference withDetermination of UricAcid,Cholesterol, and Triglycerides inCommercial Peroxidase-Coupled Assays, andthe Effectof Ferrocyanide (1986) (0)
No Cross Reactivity of Tianeptine to Tricyclic Antidepressant Immunoassays. (2021) (0)
Polymorphisms Related to Acute Coronary Syndromes and Heart Failure (2003) (0)
The Reference Range for the Anion Gap Is Dependent on the Instrument's Electrolyte Assay. (2021) (0)
The influence of pharmacogenomics on the protective effect of light-to-moderate alcohol use. (2018) (0)
AACC Academy's Pain Management LMPG: Verification of Drug Dosing with Quantitative Urine Drug Testing? (2018) (0)
Comprar Management of Food Allergens | Jesse E. Adams | 9781405167581 | Wiley (2009) (0)
On-Site Tests for Therapeutic Drugs (2002) (0)
Pharmacogenomics: Tailoring Treatment Based on Genotype (2012) (0)
Abstract 3476: Increased Prevalence of Aspirin Non-Responsiveness in Heart Failure Patients: Results from the Aspirin Resistance Testing and Initial Strategy for Treatment (ARTIST) Multicenter Trial (2007) (0)
Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics (2003) (0)
Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction (2017) (0)
A Multimarker Panel Improves Risk Prediction in Chronic Heart Failure (2011) (0)
Analytical techniques (2022) (0)
CLN8: AN ATORVASTATIN-SPECIFIC MARKER FOR COMMON MYALGIA (2014) (0)
Antiquated and novel clinical laboratory tests (2021) (0)
Chapter-04 Laboratory Perspective on Biomarkers for Acute Coronary Syndromes (2012) (0)
CARDIAC TROPONIN-T AND DIAGNOSTIC TEST EVALUATION. AUTHORS' REPLY (1995) (0)
Point-of-care testing (2021) (0)
CK-MB Activity Assays (1998) (0)
Lack of impairment due to con ﬁ rmed codeine use prior to a motor vehicle accident: Role of pharmacogenomics Journal of Forensic and Legal Medicine (2013) (0)
Abstract 17030: Multi-Center Prevalent and Incident Cohorts Replicate ST2 as a Biomarker of Disease Progression in PAH and is Associated With Right Heart Failure (2018) (0)
5: Prevalence of Aspirin Resistance in Patients Presenting to the Emergency Department with Chest Pain (2006) (0)
Blood gases, electrolytes, and iron (2021) (0)
CAN A SECOND MEASUREMENT OF COPEPTIN IMPROVE ACUTE MYOCARDIAL INFARCTION RULE OUT (2014) (0)
Evaluationand Comparisonof Immunoinhibition and Immunoprecipitation Methodsfor DifferentiatingMB from BB and Macro Formsof Creatine Kinase lsoenzymesin Patientsand HealthyIndividuals (1982) (0)
Comparing TOF and QTOF for comprehensive drug screening : do you really need fragmentation information ? (2014) (0)
580 The use of lamellar body counts as a predictor of fetal lung maturity in pregnancies complicated by diabetes (2001) (0)
Liquid-chromatography high-resolution mass spectrometry for untargeted toxicology analysis (2015) (0)
Adverse Effects (2016) (0)
Basics of Natriuretic Peptides: Practical Aspects of Assays, Potential Analytical Confounders, and Clinical Interpretation (2008) (0)
Broad spectrum drug screening using liquid chromatography quadrupole time of flight mass spectrometry : How valuable is retention time for identifying compounds ? (2014) (0)
Phenotyping vs. genotyping for pharmacogenomics: Expanded roles for LC/MS (2010) (0)
Drug metabolizing enzymes activities versus genetic variances for drug of clinical pharmacogenomic (2011) (0)
Molecular diagnostics—Genetic diseases (2021) (0)
High Sensitivity System and methods of analysis of troponin (2007) (0)
Clinical chemistry of neurological and psychiatric diseases (2021) (0)
Abstract 18580: High Sensitivity Cardiac Troponin Sex Specific 99th Percentiles Derived From Universal Sample Bank (2017) (0)
BIOMARKER MODEL FOR CORONARY ARTERY DISEASE (2016) (0)
Serum proteins and electrophoresis (2021) (0)
Improved Mortality Associated with ACE-I and Beta Blocker Therapy in Heart Failure with Preserved Ejection Fraction: An Analysis of the Biomarkers in Acute Heart Failure (BACH) Trial (2009) (0)
Concentration of hs-Troponin in small cohort of transgender patients. (2022) (0)
Promoting the value of precision medicine to the public: the power of storytelling (2018) (0)
Abstract C61: Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors (2015) (0)
Changes in academic productivity: implications for clinical laboratory research and development. (2000) (0)
Does Copeptin Provide Additional Risk Stratification in Chest Pain Patients With a Mild Troponin Elevation (2014) (0)
Corrigendum to “Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction” [Clin. Chim. Acta 346 (2004) 211–219] (2005) (0)
Abstract 16860: Warfarin Dosing in Patients with the CYP2C9*5 Variant (2010) (0)
Lack of gamma-hydroxybutyrate prevalence among an urban emergency department population. (2010) (0)
Contents Vol. 137, 2017 (2017) (0)
Preanalytical factors and test interferences (2021) (0)
Abstract: 37 PHYSIOGENOMIC CONTOURS OF STATIN SAFETY AND EFFICACY (2009) (0)
Total Polyphenol Intake Estimated by a Modified Folin – Ciocalteu Assay of Urine , (2006) (0)
Measurementof CreatineKinaseMM Sub-typeby Anion-ExchangeLiquid Chromatography (2004) (0)
Regulations and lab administration (2021) (0)
The pharmacogenomics of warfarin from the COAG and EU-PACT: where do we go from here? (2014) (0)
Corrigendum to “Biological variation of immunoglobulin heavy chain–light chain pairs in serum” [Clin Chim Acta 436 (2014) 68–71] (2015) (0)
Abstract 15015: Prognostic Value of Serial Changes of High-Sensitivity Cardiac Troponin I and T Using Reference Change Values Among Hemodialysis Patients (2015) (0)
Integrated Biomarkers in Cardiovascular Disease - Third International Symposium. (2008) (0)
Natriuretic Peptides: Basic Analytic Considerations (2016) (0)
Abstract 2213: Characteristics of Aspirin Non-Responders: Results from the Aspirin Resistance Testing and Initial Strategy for Treatment (ARTIST) Multicenter Trial (2007) (0)
442: Lower Weight Related to Elevated Liver Enzymes in Pulmonary Hypertension Patients Treated with Bosentan (2010) (0)
Pharmacogenomics and therapeutic drug monitoring (2021) (0)
Biomarkers for coronary artery disease and heart failure (2020) (0)
A Practical Approach for the Use of Biomarkers in Heart Failure (2020) (0)
Lack of γ-Hydroxybutyrate Prevalence Among An Urban Emergency Department Population (2010) (0)
Mass spectrometry : Clinical chemistry (1993) (0)
The Impact of Mass Spectrometry on Patients' Medical and Nonmedical Lives. (2020) (0)
Personalized justice: the potential use of genotyping in wrongful death investigations. (2017) (0)
FIVE-YEAR CHANGE IN N-TERMINAL FRAGMENT OF THE PROHORMONE BRAIN-TYPE NATRIURETIC PEPTIDE (NT-PROBNP) PREDICTS HEART FAILURE AND DEATH IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART AND SOUL STUDY (2013) (0)
Adrenal, thyroid hormones, and pregnancy (2021) (0)
215: Elevated Unprocessed Brain Natriuretic Peptide (proBNP) and an Increased Ratio of proBNP/BNP Are Associated with Early Heart Failure Progression in African-Americans: Results from an A-HeFT Substudy (2009) (0)
Low-dose estrogen improves serum lipids, homocysteine, and fibrinolysis without altering markers of hemostasis in elderly men (1998) (0)
121: Soluble ST2 Is Associated with Right Heart Failure and Is independently Predictive of Event Free Survival in Pulmonary Arterial Hypertension (2010) (0)
THE NATRIURETIC PEPTIDES FOR CHRONIC HEART FAILURE : GALECTIN-3 AND SOLUBLE ST 2 (2012) (0)
Hospitalization of Low Risk Chest Pain Patients With Normal Troponin and Copeptin (2016) (0)
Immunoassays for Serumand UrineMyoglobin: MyoglobinClearanceAssessedas a RiskFactorfor AcuteRenal Failure (1994) (0)
Urinalysis and stool testing (2020) (0)
Abstract 23: N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) vs. BNP for Predicting Heart Failure in Patients with Stable Coronary Artery Disease: the Heart and Soul Study. (2012) (0)
Immunology and autoimmune disease (2021) (0)
Pioneers in Clinical Chemistry: George N. Bowers, Jr., MD, and Robert B. McComb, PhD. (2017) (0)
B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure Analysis From Breathing Not Properly (BNP) Multinational Study Clinical Investigation and Reports (2002) (0)
Pancreatic markers, GI absorption, vitamins (2021) (0)
Abstract 18677: Disease Progression in Human Heart Failure is Associated With Leptin Deficiency and Ketosis (2015) (0)
A-067 The NT-proBNP level in Subclinical stage of cardiac structural or functional abnormalities among health checkups (2018) (0)
6. Creatine kinase, isoenzymes, and isoforms (2014) (0)
Low Level Troponin Interpretation In The Era Of High Sensitivity Troponins (2020) (0)
Circulating miR-122 in patients with non-toxic acute acetaminophen ingestions (2021) (0)
Abstract 2856: Effects of Various Treatments on Aspirin Resistance in Patients Presenting to the Emergency Department with Chest Pain: Preliminary Results of the Aspirin Resistance Testing and Initial Strategy for Treatment (ARTIST) Multicenter Trial (2006) (0)
Abstract 3610: Troponin and BNP: Heart Failure's Deadly Duo (2006) (0)
Chapter 2 On-Site Tests for Therapeutic Drugs (2017) (0)
MID-REGIONAL PROADRENOMEDULLIN PREDICTS LONG-TERM MORTALITY IN PATIENTS WITH CHEST PAIN (2014) (0)
Serum troponin I is more sensitive for the detection of acute ischemic myocardial injury than serum myoglobin or CK-MB (1997) (0)
REFERENCE: Barceloux DG. Medical toxicology of drug abuse: synthetic chemicals and psychoactive plants. Hoboken, NJ: Wiley, 2012, 1041 pp. (2012) (0)
LC tandem MS and TOF MS: A new paradigm for emergency department drug testing (2010) (0)
Utilization and Other Resource Management in Clinical Chemistry (2017) (0)
In Reply: Cardiac Troponin-T and Diagnostic Test Evaluation (1995) (0)
Serum 25-Hydroxyvitamin D Concentrations from Patient Groups at High Risk for Deficiency. (2019) (0)
proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain : Results from the CHOPIN trial Permalink (2015) (0)
B-type natriuretic peptide in the emergency diagnosis of diastolic dysfunction heart failure (2002) (0)
Simulataneous Assessment of Processed BNP1-32 and Unprocessed proBNP1-108 Improves Risk Stratification in Ambulatory Patients with Moderate to Severe Systolic Heart Failure: Results from the Penn Heart Failure Cohort (2009) (0)
Dr. Mario Werner (2001) (0)
Molecular Pathogenesis of Cardiovascular Disease (2006) (0)
Interference and HIL indices (2021) (0)
Release of troponin I from short-term hibernating myocardium subtending severe coronary stenosis (1996) (0)
Practice Guidelines : Clinical Utilization of Cardiac Biomarker Testing in Heart Failure WRITING GROUP MEMBERS (2007) (0)
Epidemiology, PreventionPatients with Heart Failure Have Increased Prevalence of Aspirin Resistance: Preliminary Results from the ARTIST Trial (2006) (0)
Abstract 19376: High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure (2010) (0)
Clinical chemistry questions and answers. (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan H. B. Wu?

Alan H. B. Wu is affiliated with the following schools: